CP
AVTX icon

CenterBook Partners’s Avalo Therapeutics AVTX Stock Holding History

CenterBook Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46M Buy
+132,869
New +$2.1M 0.12% 189

Other funds holding AVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

CenterBook Partners's AVTX Position: Q2 2026 in Review

CenterBook Partners opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 132,869 shares worth $2.46M. The stake represents 0.12% of the portfolio and ranks #189 among its holdings.

37 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • CenterBook Partners held 132,869 shares of Avalo Therapeutics worth $2.46M as of Q2 2026.
  • Avalo Therapeutics was a new CenterBook Partners position in Q2 2026.
  • Avalo Therapeutics made up 0.12% of CenterBook Partners's portfolio in Q2 2026, its #189 holding.
  • 37 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.